<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02519855</url>
  </required_header>
  <id_info>
    <org_study_id>V211-062</org_study_id>
    <nct_id>NCT02519855</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)</brief_title>
  <official_title>A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluated immunogenicity, safety, and tolerability of ZOSTAVAX™ Vaccine (V211)
      administered concomitantly versus nonconcomitantly with Quadrivalent Influenza Virus vaccine
      (inactivated) in participants ≥50 years of age. The primary hypotheses tested 1) the
      noninferiority of concomitant versus nonconcomitant vaccination with regard to Varicella
      zoster virus (VZV) Geometric Mean Titer (GMT) antibody responses, 2) the acceptability of
      geometric mean fold rise in VZV antibody response after concomitant vaccination, and 3) the
      noninferiority of concomitant versus nonconcomitant vaccination with regard to influenza
      virus strain-specific GMT antibody responses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2015</start_date>
  <completion_date type="Actual">January 26, 2016</completion_date>
  <primary_completion_date type="Actual">January 26, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody</measure>
    <time_frame>Baseline and 4 weeks after ZOSTAVAX™ vaccination (Week 4 for Concomitant group and Week 8 for Nonconcomitant group)</time_frame>
    <description>Anti-VZV antibodies were determined using a Glycoprotein Enzyme-linked Immunosorbent Assay. Baseline was Day 1 for the Concomitant group and Week 4 for the Nonconcomitant group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Fold Rise From Baseline in VZV gpELISA Antibody Titers</measure>
    <time_frame>Baseline and 4 weeks after ZOSTAVAX™ vaccination (Week 4 for Concomitant group and Week 8 for Nonconcomitant group)</time_frame>
    <description>Anti-VZV antibodies were determined using a Glycoprotein Enzyme-linked Immunosorbent Assay. Baseline was Day 1 for the Concomitant group and Week 4 for the Nonconcomitant group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers of H1N1-specific Influenza Virus Antibody</measure>
    <time_frame>Baseline and 4 weeks after Influenza vaccination (Week 4)</time_frame>
    <description>Antibodies to H1N1-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers of H3N2-specific Influenza Virus Antibody</measure>
    <time_frame>Baseline and 4 weeks after Influenza vaccination (Week 4)</time_frame>
    <description>Antibodies to H3N2-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers of B-Yamagata-specific Influenza Virus Antibody</measure>
    <time_frame>Baseline and 4 weeks after Influenza vaccination (Week 4)</time_frame>
    <description>Antibodies to B-Yamagata-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers of B-Victoria-specific Influenza Virus Antibody</measure>
    <time_frame>Baseline and 4 weeks after Influenza vaccination (Week 4)</time_frame>
    <description>Antibodies to B-Victoria-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">882</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>Concomitant Vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonconcomitant Vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ZOSTAVAX™</intervention_name>
    <description>A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)</description>
    <arm_group_label>Concomitant Vaccination</arm_group_label>
    <arm_group_label>Nonconcomitant Vaccination</arm_group_label>
    <other_name>V211</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo to ZOSTAVAX™</intervention_name>
    <description>A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)</description>
    <arm_group_label>Concomitant Vaccination</arm_group_label>
    <arm_group_label>Nonconcomitant Vaccination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Vaccine</intervention_name>
    <description>A single open-label administration of 0.5 mL intramuscular injection on Day 1</description>
    <arm_group_label>Concomitant Vaccination</arm_group_label>
    <arm_group_label>Nonconcomitant Vaccination</arm_group_label>
    <other_name>Fluzone, Vaxigrip</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has history of varicella or residence in a VZV-endemic area for ≥30 years

          -  Is male, female not of reproductive potential, or female of reproductive potential and
             has a negative pregnancy test and agrees to avoid becoming pregnant throughout the
             study

        Exclusion Criteria:

          -  Has history of hypersensitivity to any vaccine component

          -  Has previously received any varicella or zoster vaccine

          -  Has received an influenza vaccine for the 2015-16 season

          -  Has history of Herpes zoster

          -  Has received immunoglobulin, monoclonal antibodies, or any blood products within 5
             months before study vaccination

          -  Is pregnant or breastfeeding, or expecting to conceive during the study

          -  Has used immunosuppressant therapy

          -  Has known or suspected immune dysfunction

          -  Has experienced Guillain-Barré syndrome within 6 weeks

          -  Has severe thrombocytopenia or any other coagulation disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Levin MJ, Buchwald UK, Gardner J, Martin J, Stek JE, Brown E, Popmihajlov Z. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine. 2018 Jan 2;36(1):179-185. doi: 10.1016/j.vaccine.2017.08.029. Epub 2017 Aug 19.</citation>
    <PMID>28830693</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2015</study_first_submitted>
  <study_first_submitted_qc>August 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2015</study_first_posted>
  <results_first_submitted>December 22, 2016</results_first_submitted>
  <results_first_submitted_qc>December 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 14, 2017</results_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 901 participants were screened and 882 were randomized to one of two vaccination groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Concomitant Vaccination</title>
          <description>ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4</description>
        </group>
        <group group_id="P2">
          <title>Nonconcomitant Vaccination</title>
          <description>Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="441">Participants are included as treated</participants>
                <participants group_id="P2" count="441">Participants are included as treated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated on Day 1</title>
              <participants_list>
                <participants group_id="P1" count="440"/>
                <participants group_id="P2" count="441"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated at Week 4</title>
              <participants_list>
                <participants group_id="P1" count="432"/>
                <participants group_id="P2" count="424"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="438"/>
                <participants group_id="P2" count="437"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants are included as randomized</population>
      <group_list>
        <group group_id="B1">
          <title>Concomitant Vaccination</title>
          <description>ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4</description>
        </group>
        <group group_id="B2">
          <title>Nonconcomitant Vaccination</title>
          <description>Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="440"/>
            <count group_id="B2" value="442"/>
            <count group_id="B3" value="882"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.8" spread="7.2"/>
                    <measurement group_id="B2" value="61.3" spread="7.7"/>
                    <measurement group_id="B3" value="61.0" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="266"/>
                    <measurement group_id="B2" value="262"/>
                    <measurement group_id="B3" value="528"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody</title>
        <description>Anti-VZV antibodies were determined using a Glycoprotein Enzyme-linked Immunosorbent Assay. Baseline was Day 1 for the Concomitant group and Week 4 for the Nonconcomitant group.</description>
        <time_frame>Baseline and 4 weeks after ZOSTAVAX™ vaccination (Week 4 for Concomitant group and Week 8 for Nonconcomitant group)</time_frame>
        <population>Participants who met the inclusion criteria, were not protocol violators in a way that could influence the participant's immune response to study vaccine, received the quadrivalent influenza vaccine and ZOSTAVAX™ within the specified day ranges, and had samples for serology obtained within the specified day ranges.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Vaccination</title>
            <description>ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Vaccination</title>
            <description>Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody</title>
          <description>Anti-VZV antibodies were determined using a Glycoprotein Enzyme-linked Immunosorbent Assay. Baseline was Day 1 for the Concomitant group and Week 4 for the Nonconcomitant group.</description>
          <population>Participants who met the inclusion criteria, were not protocol violators in a way that could influence the participant's immune response to study vaccine, received the quadrivalent influenza vaccine and ZOSTAVAX™ within the specified day ranges, and had samples for serology obtained within the specified day ranges.</population>
          <units>gpELISA units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="440"/>
                <count group_id="O2" value="441"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=427, 409</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.0" lower_limit="185.6" upper_limit="228.6"/>
                    <measurement group_id="O2" value="230.5" lower_limit="208.4" upper_limit="255.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, n=409, 392</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395.6" lower_limit="363.7" upper_limit="430.4"/>
                    <measurement group_id="O2" value="482.0" lower_limit="446.4" upper_limit="520.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A lower bound of the 95% CI on the fold difference (GMT ratio [Concomitant / Nonconcomitant] at 4 weeks postvaccination) &gt;0.67 implied that the difference is statistically significantly noninferior to the prespecified clinically relevant decrease of 1.5-fold. A p-value ≤0.025 also supported a conclusion of noninferiority.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal regression model</method>
            <method_desc>GMT ratio, 95% CI and p-value were based on a longitudinal regression model adjusting for prevaccination titers and age.</method_desc>
            <param_type>GMT Ratio at 4 weeks postvaccination</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Fold Rise From Baseline in VZV gpELISA Antibody Titers</title>
        <description>Anti-VZV antibodies were determined using a Glycoprotein Enzyme-linked Immunosorbent Assay. Baseline was Day 1 for the Concomitant group and Week 4 for the Nonconcomitant group.</description>
        <time_frame>Baseline and 4 weeks after ZOSTAVAX™ vaccination (Week 4 for Concomitant group and Week 8 for Nonconcomitant group)</time_frame>
        <population>Participants who met the inclusion criteria, were not protocol violators in a way that could influence the participant's immune response to study vaccine, received the quadrivalent influenza vaccine and ZOSTAVAX™ within the specified day ranges, and had samples for serology obtained within the specified day ranges.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Vaccination</title>
            <description>ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Vaccination</title>
            <description>Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise From Baseline in VZV gpELISA Antibody Titers</title>
          <description>Anti-VZV antibodies were determined using a Glycoprotein Enzyme-linked Immunosorbent Assay. Baseline was Day 1 for the Concomitant group and Week 4 for the Nonconcomitant group.</description>
          <population>Participants who met the inclusion criteria, were not protocol violators in a way that could influence the participant's immune response to study vaccine, received the quadrivalent influenza vaccine and ZOSTAVAX™ within the specified day ranges, and had samples for serology obtained within the specified day ranges.</population>
          <units>Ratio of titers (Week 4 / Baseline)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="387"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.8" upper_limit="2.1"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.9" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A lower bound of the 95% CI on the GMFR &gt; 1.4 indicated that the Concomitant Group induces an acceptable VZV antibody response. A p-value ≤0.025 also supported this conclusion.</p_value_desc>
            <method>Longitudinal regression</method>
            <param_type>GMFR from Baseline</param_type>
            <param_value>1.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.76</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
            <estimate_desc>Estimated GMFR, 95% CI and p-value were based on a longitudinal regression model adjusting for age.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers of H1N1-specific Influenza Virus Antibody</title>
        <description>Antibodies to H1N1-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.</description>
        <time_frame>Baseline and 4 weeks after Influenza vaccination (Week 4)</time_frame>
        <population>Participants who met the inclusion criteria, were not protocol violators in a way that could influence the participant's immune response to study vaccine, received the quadrivalent influenza vaccine and ZOSTAVAX™ within the specified day ranges, and had samples for serology obtained within the specified day ranges.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Vaccination</title>
            <description>ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Vaccination</title>
            <description>Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of H1N1-specific Influenza Virus Antibody</title>
          <description>Antibodies to H1N1-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.</description>
          <population>Participants who met the inclusion criteria, were not protocol violators in a way that could influence the participant's immune response to study vaccine, received the quadrivalent influenza vaccine and ZOSTAVAX™ within the specified day ranges, and had samples for serology obtained within the specified day ranges.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="440"/>
                <count group_id="O2" value="441"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=426, 427</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9" lower_limit="45.4" upper_limit="59.3"/>
                    <measurement group_id="O2" value="50.1" lower_limit="44.3" upper_limit="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, n=409, 405</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207.3" lower_limit="185.6" upper_limit="231.7"/>
                    <measurement group_id="O2" value="200.5" lower_limit="180.3" upper_limit="222.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A lower bound of the 95% CI on the fold difference (GMT ratio [Concomitant / Nonconcomitant] at 4 weeks postvaccination) &gt;0.67 implied that the difference is statistically significantly noninferior to the prespecified clinically relevant decrease of 1.5-fold. A p-value ≤0.025 also supported the conclusion of noninferiority.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal regression</method>
            <method_desc>GMT ratio, 95% CI and p-value were based on a longitudinal regression model adjusting for prevaccination titers and age.</method_desc>
            <param_type>GMT Ratio at 4 weeks postvaccination</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers of H3N2-specific Influenza Virus Antibody</title>
        <description>Antibodies to H3N2-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.</description>
        <time_frame>Baseline and 4 weeks after Influenza vaccination (Week 4)</time_frame>
        <population>Participants who met the inclusion criteria, were not protocol violators in a way that could influence the participant's immune response to study vaccine, received the quadrivalent influenza vaccine and ZOSTAVAX™ within the specified day ranges, and had samples for serology obtained within the specified day ranges.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Vaccination</title>
            <description>ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Vaccination</title>
            <description>Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of H3N2-specific Influenza Virus Antibody</title>
          <description>Antibodies to H3N2-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.</description>
          <population>Participants who met the inclusion criteria, were not protocol violators in a way that could influence the participant's immune response to study vaccine, received the quadrivalent influenza vaccine and ZOSTAVAX™ within the specified day ranges, and had samples for serology obtained within the specified day ranges.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="440"/>
                <count group_id="O2" value="441"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=426, 427</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" lower_limit="26.2" upper_limit="33.3"/>
                    <measurement group_id="O2" value="31.1" lower_limit="27.5" upper_limit="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, n=409, 405</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298.8" lower_limit="264.1" upper_limit="338.1"/>
                    <measurement group_id="O2" value="272.0" lower_limit="241.6" upper_limit="306.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A lower bound of the 95% CI on the fold difference (GMT ratio [Concomitant / Nonconcomitant] at 4 weeks postvaccination) &gt;0.67 implied that the difference is statistically significantly noninferior to the prespecified clinically relevant decrease of 1.5-fold. A p-value ≤0.025 also supported the conclusion of noninferiority.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal regression</method>
            <method_desc>GMT ratio, 95% CI and p-value were based on a longitudinal regression model adjusting for prevaccination titers and age.</method_desc>
            <param_type>GMT Ratio at 4 weeks postvaccination</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers of B-Yamagata-specific Influenza Virus Antibody</title>
        <description>Antibodies to B-Yamagata-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.</description>
        <time_frame>Baseline and 4 weeks after Influenza vaccination (Week 4)</time_frame>
        <population>Participants who met the inclusion criteria, were not protocol violators in a way that could influence the participant's immune response to study vaccine, received the quadrivalent influenza vaccine and ZOSTAVAX™ within the specified day ranges, and had samples for serology obtained within the specified day ranges.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Vaccination</title>
            <description>ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Vaccination</title>
            <description>Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of B-Yamagata-specific Influenza Virus Antibody</title>
          <description>Antibodies to B-Yamagata-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.</description>
          <population>Participants who met the inclusion criteria, were not protocol violators in a way that could influence the participant's immune response to study vaccine, received the quadrivalent influenza vaccine and ZOSTAVAX™ within the specified day ranges, and had samples for serology obtained within the specified day ranges.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="440"/>
                <count group_id="O2" value="441"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=426, 427</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="13.3" upper_limit="16.1"/>
                    <measurement group_id="O2" value="12.6" lower_limit="11.6" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, n=409, 405</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" lower_limit="42.0" upper_limit="52.0"/>
                    <measurement group_id="O2" value="43.9" lower_limit="39.7" upper_limit="48.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A lower bound of the 95% CI on the fold difference (GMT ratio [Concomitant / Nonconcomitant] at 4 weeks postvaccination) &gt;0.67 implied that the difference is statistically significantly noninferior to the prespecified clinically relevant decrease of 1.5-fold. A p-value ≤0.025 also supported the conclusion of noninferiority.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal regression</method>
            <method_desc>GMT ratio, 95% CI and p-value were based on a longitudinal regression model adjusting for prevaccination titers and age.</method_desc>
            <param_type>GMT Ratio at 4 weeks postvaccination</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers of B-Victoria-specific Influenza Virus Antibody</title>
        <description>Antibodies to B-Victoria-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.</description>
        <time_frame>Baseline and 4 weeks after Influenza vaccination (Week 4)</time_frame>
        <population>Participants who met the inclusion criteria, were not protocol violators in a way that could influence the participant's immune response to study vaccine, received the quadrivalent influenza vaccine and ZOSTAVAX™ within the specified day ranges, and had samples for serology obtained within the specified day ranges.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Vaccination</title>
            <description>ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4</description>
          </group>
          <group group_id="O2">
            <title>Nonconcomitant Vaccination</title>
            <description>Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of B-Victoria-specific Influenza Virus Antibody</title>
          <description>Antibodies to B-Victoria-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.</description>
          <population>Participants who met the inclusion criteria, were not protocol violators in a way that could influence the participant's immune response to study vaccine, received the quadrivalent influenza vaccine and ZOSTAVAX™ within the specified day ranges, and had samples for serology obtained within the specified day ranges.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="440"/>
                <count group_id="O2" value="441"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=426, 427</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="10.3" upper_limit="12.2"/>
                    <measurement group_id="O2" value="10.4" lower_limit="9.6" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, n=409, 405</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" lower_limit="30.5" upper_limit="37.7"/>
                    <measurement group_id="O2" value="32.3" lower_limit="29.0" upper_limit="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A lower bound of the 95% CI on the fold difference (GMT ratio [Concomitant / Nonconcomitant] at 4 weeks postvaccination) &gt;0.67 implied that the difference is statistically significantly noninferior to the prespecified clinically relevant decrease of 1.5-fold. A p-value ≤0.025 also supported the conclusion of noninferiority.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal regression</method>
            <method_desc>GMT ratio, 95% CI and p-value were based on a longitudinal regression model adjusting for prevaccination titers and age.</method_desc>
            <param_type>GMT Ratio at 4 weeks postvaccination</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 28 days after any vaccination (up to Week 8)</time_frame>
      <desc>The population analyzed was all randomized participants who received at least one dose of study vaccination and had follow-up.</desc>
      <group_list>
        <group group_id="E1">
          <title>Concomitant Vaccination</title>
          <description>ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4</description>
        </group>
        <group group_id="E2">
          <title>Nonconcomitant Vaccination</title>
          <description>Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="435"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Ureteric cancer local</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="256" subjects_at_risk="435"/>
                <counts group_id="E2" subjects_affected="256" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="186" subjects_affected="153" subjects_at_risk="435"/>
                <counts group_id="E2" events="150" subjects_affected="134" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="322" subjects_affected="209" subjects_at_risk="435"/>
                <counts group_id="E2" events="335" subjects_affected="211" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="38" subjects_affected="33" subjects_at_risk="435"/>
                <counts group_id="E2" events="33" subjects_affected="32" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="125" subjects_affected="102" subjects_at_risk="435"/>
                <counts group_id="E2" events="125" subjects_affected="109" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

